TD Asset Management
OREX

TD Asset Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

TD Asset Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-29,340
Closed -$505K – 1422
2015
Q4 		$505K Sell
29,340
-220
-0.7% -$5.25K ﹤0.01% 1099
2015
Q3 		$624K Buy
29,560
+430
+1% +$14.7K ﹤0.01% 1027
2015
Q2 		$1.44M Sell
29,130
-1,480
-5% -$88.5K ﹤0.01% 904
2015
Q1 		$2.4M Buy
30,610
+3,200
+12% +$198K ﹤0.01% 811
2014
Q4 		$1.66M Sell
27,410
-2,180
-7% -$110K ﹤0.01% 860
2014
Q3 		$1.26M Buy
29,590
+10,650
+56% +$572K ﹤0.01% 873
2014
Q2 		$1.17M Buy
18,940
+9,580
+102% +$557K ﹤0.01% 883
2014
Q1 		$608K Buy
+9,360
New +$633K ﹤0.01% 988
2013
Q3 		– Sell
-2,990
Closed -$175K – 1303
2013
Q2 		$175K Buy
+2,990
New +$184K ﹤0.01% 1144

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TD Asset Management's OREX Position: Q1 2016 in Review

TD Asset Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2016, closing a stake of 29,340 shares — an estimated $505K sold.

TD Asset Management first reported a position in OREX in Q2 2013 and held it in 9 quarters. The position peaked at $2.4M in Q1 2015. 104 funds tracked by Wall St. Rank hold OREX as of Q1 2016.

  • TD Asset Management reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • TD Asset Management sold 29,340 Orexigen Therapeutics, Inc. shares in Q1 2016, an estimated $505K.
  • TD Asset Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 9 quarters.
  • TD Asset Management's Orexigen Therapeutics, Inc. position peaked at $2.4M in Q1 2015.
  • 104 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2016.

Based on TD Asset Management's 13F filing for Q1 2016, filed 5 May 2016.